Remegen's Telitacicept Phase 3 TELIGAN 104-Week Data Show 5.1 Between-Group Difference in eGFR Slope

Telitacicept's phase 3 TELIGAN trial showed a 104-week eGFR slope of -0.6 mL/min/1.73m²/year in the treatment group, with a between-group difference of 5.1. Under reduced dosing frequency in stage B, UPCR was still reduced by 60.7% versus placebo, and ESKD events numbered 0 versus 5 in the placebo group.